Article

Richard Joseph Discusses Treatment Outcomes for Metastatic Melanoma

Richard Joseph, assistant professor of medical oncology at Mayo Clinic in Jacksonville, Florida, explains how treatment outcomes for metastatic melanoma have grown in the past few years.

Richard Joseph, assistant professor of medical oncology at Mayo Clinic in Jacksonville, Florida, explains how treatment outcomes for metastatic melanoma have grown in the past few years.

Prior to drug approvals in 2011, Joseph says the median survival rate for patients with metastatic melanoma was approximately nine months. Today, it is more than 20 months, mainly due to approvals of Yervoy (iplilimumab), BRAF inhibitors and PD-1 inhibitors. This survival rate is found to be impressive, as no increase had been seen in the 30 years prior to 2011.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.